---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-046137"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:27:16.942102+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Q1 net loss $13.6M; YUPELRI sales up 6% to $58.3M

## Summary
- YUPELRI net sales of $58.3M recognized by Viatris, up 6% vs Q1 2024; Theravance's implied 35% share $20.4M.
- Net loss $13.6M vs $11.7M in Q1 2024; Non-GAAP net loss from ops $8.6M vs $4.5M.
- Revenue $15.4M entirely from Viatris collaboration, up 6% YoY.
- Cash $131M, no debt; reaffirming all financial guidance.
- CYPRESS study open label enrollment nearing completion, final patient expected by late summer; top-line data ~6 months later.

## SEC filing metadata
- accession: 0001104659-25-046137
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465925046137/0001104659-25-046137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465925046137/tm2514363d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-046137
- JSON: https://secwatch.observer/filing/0001104659-25-046137.json
- Plain text: https://secwatch.observer/filing/0001104659-25-046137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.